As anti-angiogenic strategy such as anti-VEGF therapy is another potential treatment in ovarian cancer, it potentiates the possibility of FILIP1L being a therapeutic target in ovarian cancer. The gene discussed is VEGFA; the disease is ovarian carcinoma.